Please provide your email address to receive an email when new articles are posted on . Lirentelimab was safe and effective in the long-term treatment of patients with eosinophilic gastritis and/or ...
SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and ...
– Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis ...
Infectious complications of CD20 x CD3 bispecific antibody therapy in patients with B-cell lymphoma. Real-life use of G-CSF in non-small cell lung cancer (NSCLC): Secondary data analysis from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results